Proton beam re-irradiation for gastrointestinal malignancies: a systematic review

Andrew R. Barsky, Vishruth K. Reddy, John P. Plastaras, Edgar Ben-Josef, James M. Metz, Andrzej P. Wojcieszynski

Department of Radiation Oncology, Perelman School of Medicine of the University of Pennsylvania, Perelman Center for Advanced Medicine, Philadelphia, PA, USA


Correspondence to: Andrzej P. Wojcieszynski, MD. Department of Radiation Oncology, Perelman Center for Advanced Medicine, TRC 4 West, 3400 Civic Center Boulevard, Philadelphia, PA 19104, USA. Email: Andrzej.Wojcieszynski@uphs.upenn.edu.

Background: Radiotherapy (RT) is part of the standard of care management of most gastrointestinal (GI) cancers. Even with advanced RT, systemic therapy, and surgical techniques, locoregional recurrences or second primary cancers can still occur within previously irradiated fields, which can present challenges in delivering effective and safe treatment. Options for reirradiation are often limited, but given the favorable dosimetric aspects of proton-beam RT, it may provide an effective and safe re-irradiation option for patients with recurrent or second primary GI cancers.

Methods: We conducted a systematic review as per the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement protocol, assessing for reports of proton-beam reirradiation for recurrent or second primary GI cancers, primarily via PubMed. From the initial 373 articles identified, 7 articles were ultimately included in the analysis.

Results: The 7 included studies reported on proton-beam re-irradiation for the following disease sites: esophageal (n=2), pancreas (n=1), liver (n=2), rectal (n=1), and anal (n=1). Study sizes varied from as few as 1 to as many as 83 patients. Across studies, in patients who presented with tumor-related symptoms, palliation (stability/improvement) was achieved in 80–100% of the cases. Local control rates, with variable follow-up, ranged from 36–100%. All median overall survival values, when reported, were greater than 1 year. Across both liver studies, there were no cases of radiation-induced liver disease (RILD) from proton-beam re-irradiation. Across all studies, there were 2 acute (esophagopleural fistula in esophageal cancer, small bowel perforation in pancreatic cancer) and 1 late (esophageal ulcer in esophageal cancer) grade 5 toxicities, all favored to be due to progressive disease, rather than proton-beam re-irradiation. Two studies (1 esophageal, 1 rectal) generated comparison photon plans. One found that proton therapy reduced mean heart and lung doses, spinal cord dose, and lung V5Gy as compared to photon treatment, while resulting in higher lung V20Gy and V30Gy. The other found that protons decreased bowel V10Gy, V20 Gy, and the dose to 200 and 150 cc of bowel, as compared to photons.

Conclusions: Based upon the published experiences, proton-beam re-irradiation for recurrent or second primary GI cancers appears effective for palliation, with good disease-control, limited toxicity, favorable dosimetry, and overall compares well with published non-proton-beam experiences. Given short follow-up, additional studies are warranted to determine if dosimetric advantages from proton therapy will translate into comparative toxicity benefits.
Introduction

Radiotherapy (RT) plays an important role in the management of many gastrointestinal (GI) cancers, and is used in the palliative, neoadjuvant, adjuvant, and definitive setting for patients with esophageal (1), gastric (2), pancreatic (3,4), hepatobiliary (5,6), rectal (7), and anal cancers (AC) (8).

Even with advanced RT, systemic therapy, and surgical options available, many patients will experience locoregionally recurrent (LRR) disease, or develop a new primary cancer within a previously-irradiated field. Retreatment by any modality presents a challenge for both patients and physicians in regards to how best to deliver treatment effectively and safely. In this setting, management options frequently include one or a combination of RT, systemic therapy, surgery, ablative therapy, radioisotope therapy, clinical trials, or supportive care. From an RT standpoint, photon re-irradiation options exist. While there are few published randomized data in the re-irradiation setting, in recurrent head and neck (HN) cancer, a randomized trial assessing the role of post-operative re-irradiation with chemotherapy following salvage surgery found that patients who received post-operative CRT [with conventional RT or three-dimensional conformal RT (3D-CRT)] after salvage surgery experienced significantly-improved disease-free survival (DFS), as compared to patients who underwent salvage surgery alone, though at the expense of increased acute and late toxicity (9).

In GI malignancies, non-randomized data exist for photon re-irradiation with older techniques, with mixed results. A series of 10 patients that received photon re-irradiation [non-intensity modulated RT (IMRT)] for recurrent EC found that RT produced a tumor response in 50% of patients 3 months from the end of re-irradiation, with a median follow-up of 4.9 months, albeit with development of grade 5 tracheoesophageal fistulae in 3 patients (10). A prospective study of 72 patients with locally recurrent (LR) unresectable RC who received re-irradiation with hyperfractionated 3D-CRT and concurrent capecitabine found an overall response rate and clinical benefit rate of 59.7% and 93.1%, respectively, with grade 3–4 diarrhea and granulocytopenia in 9.7% and 8.3%, respectively, and a 1.4% rate of small bowel obstruction (SBO) (11).

Given the potential for re-irradiation to control recurrent or new primary disease, there has been interest in applying more modern RT techniques to minimize the associated toxicity. Within photon re-irradiation, IMRT has been used to re-irradiate LR RC, with successful palliation in 55.6% of patients, 61.3% and 47.3% 1- and 2-year LC, and 32.3% and 3.2% grade 2 and 3 acute toxicity rates, respectively (12). Within IMRT, groups at Harvard (13), Stanford, and Johns Hopkins have studied the use of stereotactic body RT (SBRT) for re-irradiation for recurrent PC, with LC ranging from 62–78% and a 6–7% risk of SBO (14).

With evidence that modern photon re-irradiation techniques may permit efficacious and safe delivery of RT for recurrent or new primary disease, there has also been interest in the use of particle therapies, like carbon-ion therapy (CIT) and proton-beam therapy (PBT) to further lessen the toxicity of RT and improve the therapeutic ratio. A prospective report of CIT to re-irradiate a variety of cancers (over one-third of which were RC or HCC) demonstrated 71% and 60% 1- and 2-year LC, with no grade ≥2 acute toxicities, 18% grade 3 late toxicities, and no grade ≥4 late toxicities (15). Another report of CIT re-irradiation, in 19 patients with LR RC, found 79% 1-year LC, with no grade ≥3 toxicities at a median follow-up of 7.8 months (16).

PBT is another particle therapy that has garnered recent interest, given the favorable properties of PBT dose deposition. PBT can deliver equivalent doses to targets as would photons while sparing integral dose to OARs, which could potentially reduce toxicity (17). PBT has been used clinically in the up-front setting to treat primary brain tumors (18), HN cancer (19,20), thoracic malignancies (21-23), breast cancer (24,25), gynecologic cancers (26), prostate cancer (27,28), and GI malignancies (29) with reasonable efficacy and safety. PBT has been used in the re-irradiation setting to treat adult and pediatric central nervous system tumors (30,31), HN cancer (32,33), thoracic malignancies (34,35), breast cancer (36), gynecologic cancers (37), and GI malignancies (38), also with reasonable efficacy and safety. At present, a dedicated review of PBT re-irradiation for GI
malignancies has not been published. Such a review could potentially better familiarize clinicians with the use of PBT re-irradiation in this setting, better inform their decision-making discussions with patients and colleagues, and pave the way for further study. Herein, we provide a systematic review of the published experiences of PBT re-irradiation in patients with recurrent or second primary GI malignancies.

**Methods**

We conducted our systematic review as per the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement protocol (39). Inclusion criteria consisted of any English language published literature reporting on patients with recurrent or second primary GI malignancies treated with PBT re-irradiation (e.g., PBT within the field of a prior RT course). Comparison and/or outcome measures assessed were any cancer-control outcomes, survival outcomes, symptom-relief outcomes, and/or acute or late toxicities. PubMed was the primary information source (most recently searched on July 21, 2019, without other date constraints), while a minority of articles were identified from within the text of articles found in PubMed. Search terms in PubMed included combinations of the words “proton”, “beam”, “therapy”, “radiation”, “radiotherapy”, “re-irradiation”, “re-treatment”, and “repeat”, with combinations of hyphenation to maximize search output.

Using the search criteria above and in-text article identification, 373 articles were identified (Figure 1). A total of 10 duplicate articles were excluded, as they represented initial reports of subsequently updated published cohorts. Of the remaining 363 articles, 352 were excluded, as they did not fully meet the inclusion criteria above, as assessed by 3 authors. Commonly, the reasons for exclusion were non-PBT re-irradiation, receipt of only one RT course, non-GI malignancies receiving re-irradiation, or pre-clinical work (physics, dosimetry, or cell biology studies without disease/symptom-control or toxicity outcomes), among others. Of the remaining 11 articles, 4 articles were ineligible due to being review articles, thus establishing our final inclusion of 7 primary reports for quantitative synthesis. Within these 7 reports, we manually extracted data from the published articles regarding initial cancer-directed treatments, with particular attention to RT, as well as subsequent cancer-directed treatments, with particular attention to PBT re-irradiation and any concurrent therapies administered. We then extracted the comparison and outcome measures described above, as well as any accompanying dosimetric data, when present. Given the substantial variability in disease site, study size, and methodologies used in the 7 studies included, neither meta-analysis nor other

Figure 1 PRISMA consort diagram depicting search and selection process for systematic review. PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses.
comparative statistical methodologies were performed.

**Results**

**Esophageal cancer**

Two published experiences of PBT re-irradiation for EC are displayed in Table 1. The first is a 14-patient prospective feasibility trial that enrolled patients with recurrent or second primary EC with Karnofsky performance statuses (KPS) >60, life expectancies >3 months, and ≥3-month intervals from prior RT courses (40). During the initial courses of RT, patients were treated for stage I (7%), stage II (43%), or stage III (21%) EC, or non-EC (29%) that received RT in the subsequent field of their EC PBT. Four (29%) previously underwent esophagectomy. The median prior RT dose was 54 Gy (range, 25.5–70 Gy). Patients who met the above criteria then received PBT re-irradiation to gross disease to a median re-irradiation dose of 54 GyE (range, 50.4–61.2 GyE) in 1.8 GyE fractions for all but one, and to a cumulative dose of 109.8 GyE (range, 76–129.4 GyE), at a median interval of 32 months (range, 10–307 months) from their prior RT courses. PBT technique was 2–3-beam passive scattering (PS) in 13 (93%) patients and pencil-beam scanning (PBS) in 1 (7%) patient, with either cord-sparing anterior fields (with anterior bolus as needed) or heart/lung-sparing posterior fields based upon tumor location. Two (14%) patients received 30% and 14% of their treatments with IMRT as a result of pleural effusion formation and PBT downtime, respectively. Most patients (79%) received concurrent chemotherapy with PBT, most commonly 5-fluorouracil- (5-FU) based (73%). The majority had adenocarcinoma (71%) and lower esophageal tumors (64%). The primary endpoints included feasibility and acute toxicity. The secondary endpoints were late complications, disease control, and OS. At a median follow-up of 10 months (range, 2–25 months) from the start of re-irradiation, 8 of 10 patients that presented with dysphagia had improved or stable symptoms. LRR and DM were observed in 9 (64%) and 6 (43%) patients, respectively. The median and 1-year OS were 14 months (95% CI, 7–21 months) and 71%, respectively. Acute grade ≥3 toxicities included grade 3 dehydration (n=2, 14%), dysphagia requiring feeding tube or stent (n=2, 14%), GI bleed (n=1, 7%), hyponatremia (n=1, 7%), pneumonia (n=1, 7%), weight loss (n=1, 7%), and grade 5 esophagopleural fistula (n=1, 7%), favored to be due to tumor progression rather than PBT, as this occurred following the second fraction). Late grade ≥3 toxicities included grade 3 dysphagia (n=1, 7%), esophageal stenosis (n=1, 7%), esophageal ulcer (n=1, 7%), heart failure (n=1, 7%), and grade 5 esophageal ulcer (n=1, 7%, favored to be due to LR/persistence rather than PBT).

Patel et al. (41) present a retrospective case series of 3 patients who received thoracic RT as part of treatment for prior malignancies and subsequently developed esophageal squamous cell carcinoma (SCC), for which they underwent PBT re-irradiation. The first patient previously received involved-field RT to a dose of 36 Gy with 6 cycles of R-CHOP for mediastinal diffuse large B-cell lymphoma, in addition to additional systemic therapy and stem-cell transplant, complicated by pulmonary fibrosis and cardiomyopathy. Five years after his initial RT course, he was found to have cT2N0 esophageal SCC of the mid-esophagus. The second patient previously received mantle/para-aortic RT to a dose of 36 Gy for Hodgkin lymphoma, complicated by coronary artery disease and aortic stenosis. Thirty years after her initial RT course, she was found to have a cT3N1 esophageal SCC of the mid-esophagus. The third patient previously received whole-lung RT to 15 Gy for metastatic osteosarcoma, with multiple cycles of doxorubicin-based chemotherapy, complicated by cardiomyopathy and arrhythmias requiring a pacemaker. Forty-one years after her initial RT course, she was found to have a cT3N0 esophageal SCC of the lower esophagus. All 3 patients received PBT re-irradiation to an initial dose of 45 GyE with a clinical tumor volume (CTV) expansion of 3.5 cm superior/inferior and 1.5 cm circumferentially in 1.8 GyE fractions, with 2 (67%) receiving a boost of 5.4 GyE to primary disease. The median cumulative dose was 81 GyE (range, 65.4–86.4 GyE). PBT technique was 1–2-beam posterior-oblique PS and 1-beam posterior-anterior PBS in 2 (67%) and 1 (33%) patients, respectively. All patients received concurrent chemotherapy (67% FOLFOX, 33% carboplatin/paclitaxel), and underwent esophagectomy following RT (67% initially unplanned). At a median follow-up of 26 months (range, 22–72 months) from esophagectomy, all 3 patients were alive, without evidence of recurrent or metastatic disease. Acute toxicities included mild/moderate odynophagia (n=2, 67%), esophageal stricture requiring balloon dilation (n=1, 33%), hematemesis (n=1, 33%), and moderate/severe esophagitis (n=1, 33%). The only late toxicity reported was intra-operative cardiac arrest and cardiogenic shock during esophagectomy, requiring extracorporeal membrane oxygenation, from which he recovered. In addition, comparison volumetric-modulated
Table 1  Treatment and outcome details for proton-beam therapy re-irradiation in patients with recurrent or second primary esophageal cancer

<table>
<thead>
<tr>
<th>Study (year)</th>
<th>Number of patients</th>
<th>Stage</th>
<th>Tumor details</th>
<th>Prior RT (median dose)</th>
<th>Median time to re-irradiation</th>
<th>PBT re-irradiation details</th>
<th>Non-RT treatments</th>
<th>Median follow-up</th>
<th>Disease-control outcomes</th>
<th>Survival outcomes</th>
<th>Toxicity outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fernandes et al. [2016] (40)</td>
<td>14</td>
<td>Initial stage I (n=1, 7%), initial stage II (n=6, 43%), initial stage III (n=3, 21%), initial non-EC (n=4, 29%)</td>
<td>Upper esophagus (n=5, 36%), lower esophagus (n=9, 64%)</td>
<td>54 Gy (range 25.5–70 Gy)</td>
<td>32 months (range 10–307 months)</td>
<td>54 GyE (range 50.4–61.2 GyE), 1.8 GyE/fraction (n=11, 79%)</td>
<td>Concurrent chemotherapy (n=13, 93%), PS (n=13, 93%), PBS (n=1, 7%)</td>
<td>10 months (range 2–25 months)</td>
<td>9/14 (64%) with LRR, 6/14 (43%) with DM, 8/10 (80%) with improved/stable dysphagia</td>
<td>1-year OS 71%</td>
<td>Acute: grade 3: dehydration (n=2), dysphagia (n=2), GI bleed (n=1), hyponatremia (n=1), pneumonia (n=1), weight loss (n=1); grade 5: esophagopleural fistula (n=1). Late: grade 3: dysphagia (n=1), esophageal stenosis (n=1), esophageal ulcer (n=1), heart failure (n=1); grade 5: esophageal ulcer (n=1)</td>
</tr>
<tr>
<td>Patel et al. [2019] (41)</td>
<td>3</td>
<td>Initial DLBCL, now cT2N0 EC (n=1), initial HL, now cT3N1 EC (n=1), initial osteosarcoma, now cT3N0 EC (n=1)</td>
<td>SCC (n=3, 100%), mid esophagus (n=2, 67%), lower esophagus (n=1, 33%)</td>
<td>36 Gy (range 15–36 Gy)</td>
<td>30 years (range 5–41 years)</td>
<td>50.4 GyE (range 45–50.4 GyE), 1.8 GyE/fraction (n=3, 100%), PS (n=2, 67%), PBS (n=1, 33%)</td>
<td>Concurrent FOLFOX chemotherapy (n=3, 100%), PSA (n=2, 67%), PBS concurrent carboplatin/paclitaxel chemotherapy (n=1, 33%), post-PBT esophagectomy (n=3, 100%)</td>
<td>26 months (range 22–72 months)</td>
<td>0/3 (0%) with LRR or DM</td>
<td>3/3 (100%) alive at 22, 26, and 72 months post-op</td>
<td>Acute: mild/moderate odynophagia (n=2), esophageal stricture (n=1), hematemesis (n=1), moderate/severe esophagitis (n=1). Late: intra-op cardiac arrest (n=1)</td>
</tr>
</tbody>
</table>

RT, radiation therapy; PBT, proton-beam therapy; EC, esophageal cancer; SCC, squamous cell carcinoma; Gy, Gray; GyE, Gray-equivalent; PS, passive scatter; PBS, pencil-beam scanning; LRR, locoregional recurrence; DM, distant metastasis; OS, overall survival; CI, confidence interval; GI, gastrointestinal; DLBCL, diffuse large B-cell lymphoma; HL, Hodgkin’s lymphoma.
arc therapy (VMAT) plans were designed, with similar target and OAR constraints, which showed reduced OAR doses and equal target coverage with PBT, with the exception of the lung V20Gy/V30Gy parameters in the 2 patients treated with PS.

Pancreatic cancer

One published experience of PBT re-irradiation for PC is displayed in Table 2 (42). This was a 15-patient report that included patients treated on a prospective safety and feasibility trial (n=13) that enrolled patients with isolated LR PC with KPS ≥60, life expectancies >3 months, and ≥3-month intervals from prior RT courses, or on an institutional PBT registry who met the aforementioned criteria (n=2). During the initial courses of RT, patients were treated for resectable (67%), borderline resectable (20%), or unresectable (13%) PC of the pancreatic head (67%), body (20%), or tail (13%). Most patients initially underwent resection with either neoadjuvant (27%) or adjuvant CRT (60%), while the remainder underwent definitive CRT (13%). The median prior RT dose was 50.4 Gy (range, 30–59.4 Gy). Patients who met the above criteria then received PBT re-irradiation to gross disease and high-risk regions with an internal target volume (ITV) for respiratory motion and 0.5–1 cm planning target volume (PTV) margin to a median re-irradiation dose of 59.4 GyE (range, 37.5–59.4 GyE) in 1.8 GyE fractions for all but one, to a median CTV/ITV volume of 71 cc (range, 15–200 cc), at a median interval of 26.7 months (range, 7–90 months) from their prior RT courses. PBT technique was 2–3-beam PS based upon tumor location and prior OAR doses. One (7%) patient received 35% of RT with VMAT to optimize duodenal sparing. Most patients (67%) received concurrent chemotherapy with PBT, all 5-FU-based. PBT targets included nodal regions in 73% (celiac, n=6, 55%; aortocaval, n=2, 18%; porta hepatis, n=2, 18%; superior mesenteric, n=1, 9%) and/or surgical bed/progressive primary disease after definitive CRT in 47% of patients. At a median follow-up of 15.7 months (range, 2–48 months) from the start of re-irradiation, 6 of 7 patients that presented with symptomatic, painful LR experienced pain palliation. LRR (in-field) and DM were observed in 4 (27%) and 13 (87%) of patients, respectively, with one of the LR’s occurring in a patient treated to a palliative RT dose. The median and 1-year OS were 16.7 months (95% CI, 4.7–36 months) and 67%±12%, respectively. Patients that received concurrent chemotherapy had significantly longer median OS (22.8 months) than those that did not (7.6 months, P=0.003). Of the 7 patients with elevated cancer antigen 19-9 levels prior to PBT, 5 (71%) experienced decreased levels after PBT. Acute grade ≥2 toxicities were 88% (95% CI, 80–95%) and 49% (95% CI, 38–61%), respectively. There were no late grade ≥2 toxicities.

Liver tumors

Two published experiences of PBT re-irradiation for liver tumors are displayed in Table 3. The first is an 83-patient (92 tumors) retrospective report of PBT re-irradiation in patients with recurrent or second primary HCC (43). In this report, patients received PBT re-irradiation if it was deemed that non-RT treatments would not be feasible, or if the patient refused non-RT treatments. The median initial RT dose was 71 GyE (all delivered with PBT), with regimens most commonly consisting of 66 GyE in 10 fractions (n=42, 46%), 72.6 GyE in 22 fractions (n=34, 37%), or 74 GyE in 37 fractions (n=13, 14%), to a median CTV volume of 35 cc (range, 3–936 cc). 64% of patients received initial non-RT treatments as well. A total of 91, 16, and 3 tumors were treated in the 2nd, 3rd, and 4th PBT courses. Patients received PBT re-irradiation to a median 2nd course dose of 70 GyE (all double-scatter technique), with regimens most commonly consisting of 66 GyE in 10 fractions (n=30, 33%), 72.6 GyE in 22 fractions (n=30, 33%), or 74 GyE in 37 fractions (n=17, 19%), to a median CTV volume of 29 cc (range, 4–665 cc). At a median follow-up of 45 months (range, 5–153 months) from the start of the initial PBT course, the median OS was 61 months (95% CI, 50–71 months), and 2- and 5-year OS were 88% (95% CI, 80–95%) and 49% (95% CI, 38–61%), respectively. There were no acute grade ≥2 toxicities and no cases of radiation-induced liver disease (RILD).

McDuff et al. (44) present a retrospective report of 49 patients (64 tumors) who received re-irradiation to the liver for recurrent or second primary liver tumors. Of note, only 5 patients (10%) received re-irradiation using PBT. In this cohort, patients with HCC received re-irradiation if they were felt to be suboptimal candidates for other local therapies. Patients with IHCC received re-irradiation if tumor anatomy precluded resection or they progressed after initial adjuvant RT. Patients with liver metastases...
<table>
<thead>
<tr>
<th>Study (year)</th>
<th>Number of patients</th>
<th>Initial stage, tumor, and treatment details</th>
<th>Recurrence location</th>
<th>Prior RT (median dose)</th>
<th>Median time to re-irradiation</th>
<th>PBT re-irradiation details</th>
<th>Non-RT treatments</th>
<th>Median follow-up</th>
<th>Disease-control outcomes</th>
<th>Survival outcomes</th>
<th>Toxicity outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Boimel et al. [2017] (42)</td>
<td>15</td>
<td>Resectable (n=10, 67%), Borderline resectable (n=3, 20%), unresectable (n=2, 13%), pancreatic head (n=10, 67%), pancreatic body (n=3, 20%), pancreatic tail (n=2, 13%), surgery (n=13, 87%), definitive CRT (n=2, 13%)</td>
<td>Nodal (n=11, 73%): celiac (n=6, 55%), aortocaval (n=2, 18%), porta hepatitis (n=2, 18%), SMA (n=1, 9%), Surgical bed/primary (n=7, 47%): surgical bed (n=2, 29%), remnant pancreas/surgical bed (n=2, 29%), primary progression after definitive CRT (n=2, 29%), duodenum/lesser curvature/surgical bed (n=1, 14%)</td>
<td>50.4 Gy (range, 30–59.4 Gy)</td>
<td>26.7 months (range, 7–90 months)</td>
<td>59.4 GyE (range, 37.5–59.4 GyE), 1.8 GyE/fraction (n=14, 93%), 2.5 GyE/fraction (n=1, 7%), PS (n=15, 100%), 71 cc CTV/ITV size (range, 15–200 cc)</td>
<td>Concurrent chemotherapy (n=10, 67%, all 5-FU-based)</td>
<td>15.7 months (range, 2–48 months)</td>
<td>4/15 (27%) with in-field LRR, 13/15 (87%) with DM, 6/7 (87%) with pain palliation, 5/7 (71%) 1-year OS with reduction in CA 19-9 if elevated pre-PBT</td>
<td>Median OS 16.7 months (95% CI, 4.7–36 months), 1-year OS 67%±12%</td>
<td>Acute: grade 3: anorexia (n=1), fatigue (n=1); grade 4: bleeding duodenal ulcer (n=1); grade 5: small bowel perforation (n=1). Late: no grade ≥2 toxicities</td>
</tr>
</tbody>
</table>

RT, radiation therapy; PBT, proton-beam therapy; CRT, chemoradiotherapy; SMA, superior mesenteric artery; Gy, Gray; GyE, Gray-equivalent; PS, passive scatter; CTV, clinical target volume; ITV, internal target volume; cc, cubic centimeters; 5-FU, 5-fluorouracil; LRR, locoregional recurrence; DM, distant metastasis; CA 19-9, cancer antigen 19-9; OS, overall survival; CI, confidence interval.
<table>
<thead>
<tr>
<th>Study (year)</th>
<th>Number of patients</th>
<th>Tumor/patient details</th>
<th>Prior non-RT treatments</th>
<th>Prior RT (median dose)</th>
<th>Median time to re-irradiation (median dose)</th>
<th>PBT re-irradiation details (median dose)</th>
<th>Non-RT treatments</th>
<th>Median follow-up</th>
<th>Disease-control outcomes</th>
<th>Survival outcomes</th>
<th>Toxicity outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oshiro et al. 2017</td>
<td>83 (92 tumors)</td>
<td>HCC (n=83, 100%), 92/91/16/3 tumors treated in 1st/2nd/3rd/4th PBT courses, CP at A (n=57, 69%); B (n=25, 30%); C (n=1, 1%), tumor thrombosis in all courses (n=16, 19.2%)</td>
<td>Yes (n=53, 64%), no (n=30, 36%)</td>
<td>71 GyE, 66 GyE, 10 GyE (n=42, 46%), 72.6 GyE, 22.6 GyE (n=16, 19%)</td>
<td>Not reported</td>
<td>2nd PBT course: 70 GyE, 66 GyE, 10 GyE (n=42, 46%)</td>
<td>Not reported</td>
<td>45 months from start of 1st PBT (range 5–153 months)</td>
<td>Not reported</td>
<td>Median OS 61 months from 1st PBT (95% CI, 50–71 months), 2-year OS 88% (95% CI, 80–95%), 5-year OS 49% (95% CI, 38–61%)</td>
<td>Acute: no grade ≥3 toxicities, Radiation-induced liver disease (RILD): 0/83 (0%), toxicity outcomes</td>
</tr>
<tr>
<td>McDuff et al. 2019</td>
<td>49 (n=5, 10% received PBT re-irradiation)</td>
<td>HCC (n=19, 39%), IHCC (n=7, 14%), liver metastases in 1st/2nd/3rd/4th PBT courses, CP at A (n=33, 67%), B (n=12, 24%), C (n=4, 8%), normal liver EQD2 (n=6, 12%)</td>
<td>Surgery (n=18, 37%)</td>
<td>GTV EQD2 (α/β=10): 60 Gy (IQR, 59.1–83.3 Gy), normal liver EQD2 (α/β=3): 9.7 Gy (IQR, 6.5–12.9 Gy), 5 fractions (n=33, 67%), 15 fractions (n=12, 24%), median GTV volume 59 cc (IQR, 18–189 cc)</td>
<td>Concurrent chemotherapy (n=6, 12%)</td>
<td>10.5 months</td>
<td>1-year LR 46%, 1-year OS for HCC/IHCC 33%, 1-year OS for liver metastases 61% (P=0.0047) (n=2)</td>
<td>Median OS 14 months (IQR, 7–22 months), 2-year OS 80% (95% CI, 70–90%), 5-year OS 49% (95% CI, 38–61%)</td>
<td>Acute: grade 3: nausea/vomiting, late: no grade ≥2 toxicities, Classic RILD: 0/49 (0%), non-classic RILD: 2/49 (4%) (neither patient received PBT re-irradiation)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

RT, radiation therapy; PBT, proton-beam therapy; HCC, hepatocellular carcinoma; CP, Child-Pugh score; GyE, Gray-equivalent; Fx, fractions; CTV, clinical tumor volume; DS, double-scatter; OS, overall survival; CI, confidence interval; RILD, radiation-induced liver disease; IHCC, intrahepatic cholangiocarcinoma; TACE, transcatheter arterial chemoembolization; RFA, radiofrequency ablation; MWA, microwave ablation.
received re-irradiation if they had oligometastatic disease or limited local progression with controlled systemic disease. During the initial courses of RT, patients were treated for HCC (39%), IHCC (14%), or liver metastases (47%). Initial non-RT local treatments consisted of surgery (37%), transcatheter arterial chemoembolization (8%), radiofrequency ablation (8%), and microwave ablation/cryotherapy (6%). The median prior RT doses to the gross tumor volume (GTV) \([\text{equivalent dose in 2 Gy fractions (EQD2), } \alpha/\beta=10]\) and normal liver (EQD2, \(\alpha/\beta=3\)), were 60 Gy [interquartile range (IQR), 60–76.3 Gy] and 13.9 Gy (IQR, 9.1–19.4 Gy), respectively. The median prior GTV volume was 59 cc (IQR, 18–189 cc). Patients who met the above criteria then received re-irradiation to the GTV (median volume, 25 cc, IQR, 12–76 cc), with an ITV for target motion, a 0–0.5 cm margin for CTV, and an additional 0.5 cm margin for PTV, at a median of 9.1 months (range, 6.7–14.9 months) from their prior RT courses. The median re-irradiation doses to the GTV (EQD2, \(\alpha/\beta=10\)) and normal liver (EQD2, \(\alpha/\beta=3\)) were 60 Gy (IQR, 59.1–83.3 Gy) and 9.7 Gy (IQR, 6.5–12.9 Gy), respectively, delivered most commonly in 5–6 fractions (67%) or 15 fractions (24%), occasionally with concurrent chemotherapy (12%). The median follow-up was 10.5 months. The 1-year LR rate was 46% for the whole cohort, 33% for patients with HCC/IHCC, and 61% for patients with liver metastases \((P=0.0047)\). The median OS for the whole cohort was 14 months (IQR, 7–22 months), with 1-year OS for patients with HCC/IHCC and liver metastases \((P=0.0047)\), respectively. Acute grade \(\geq 3\) toxicities included grade 3 nausea/vomiting \((n=2, 4\%)\). There were no late grade \(\geq 3\) toxicities or cases of classic RILD. There were 2 cases \((4\%)\) of non-classic RILD, but neither patient received PBT re-irradiation.

### Rectal cancer

One published experience of PBT re-irradiation for RC is displayed in Table 4 (45). This was a 7-patient report that included patients treated on a prospective toxicity and feasibility study with LR RC with KPS KPS ≥60, life expectancies ≥3 months, and ≥3 months since prior RT courses. This was a 7-patient report that included patients treated on a prospective study with LR RC with KPS KPS ≥60, life expectancies ≥3 months, and ≥3 months since prior RT courses. The median prior RT dose was 50.4 Gy (range, 44–86.4 Gy),

---

<table>
<thead>
<tr>
<th>Study</th>
<th>Number of initial stage, tumor, and treatment details</th>
<th>Prior RT doses</th>
<th>Median time to PBT re-irradiation</th>
<th>Non-RT treatments</th>
<th>Median follow-up</th>
<th>Survival outcomes</th>
<th>Toxicity outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Berman et al. [2014] (45)</td>
<td>Stage I ((n=1, 14%)), stage II ((n=2, 29%)), stage III ((n=3, 43%)), stage IV ((n=1, 14%))</td>
<td>50.4 Gy (\text{median dose})</td>
<td>39 months (\text{range, 30–50 months})</td>
<td>Concurrent chemotherapy ((n=6, 83%)), all 5-FU-based</td>
<td>7.6 months (\text{range, 7–9 months})</td>
<td>3/7 ((43%)) with LRR/local progression, 1/7 ((14%)) with DM, 6/6 ((100%)) with pain palliation</td>
<td>Acute: grade 3: diarrhea ((n=3)), abdominal pain ((n=1)). Late: grade 4: bowel obstruction ((n=1)), bowel obstruction ((n=1))</td>
</tr>
</tbody>
</table>

### Table 4

<table>
<thead>
<tr>
<th>Study</th>
<th>Number of initial stage, tumor, and treatment details</th>
<th>Prior RT doses</th>
<th>Median time to PBT re-irradiation</th>
<th>Non-RT treatments</th>
<th>Median follow-up</th>
<th>Survival outcomes</th>
<th>Toxicity outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Berman et al. [2014] (45)</td>
<td>Stage I ((n=1, 14%)), stage II ((n=2, 29%)), stage III ((n=3, 43%)), stage IV ((n=1, 14%))</td>
<td>50.4 Gy (\text{median dose})</td>
<td>39 months (\text{range, 30–50 months})</td>
<td>Concurrent chemotherapy ((n=6, 83%)), all 5-FU-based</td>
<td>7.6 months (\text{range, 7–9 months})</td>
<td>3/7 ((43%)) with LRR/local progression, 1/7 ((14%)) with DM, 6/6 ((100%)) with pain palliation</td>
<td>Acute: grade 3: diarrhea ((n=3)), abdominal pain ((n=1)). Late: grade 4: bowel obstruction ((n=1)), bowel obstruction ((n=1))</td>
</tr>
<tr>
<td>Study (year)</td>
<td>Number of patients</td>
<td>Initial tumor details</td>
<td>Recurrence location</td>
<td>Prior RT (dose)</td>
<td>Time to re-irradiation</td>
<td>PBT re-irradiation details</td>
<td>Non-RT treatments</td>
</tr>
<tr>
<td>-------------------</td>
<td>--------------------</td>
<td>---------------------------------------------------------------------------------------</td>
<td>---------------------</td>
<td>-----------------</td>
<td>----------------------</td>
<td>-------------------------------------------------------------------------------------------</td>
<td>-------------------</td>
</tr>
<tr>
<td>Apinorasethkul et al. [2016] (46)</td>
<td>1</td>
<td>Initial low-risk prostate cancer, now cT3N0 AC</td>
<td>3–8 cm from the anal verge</td>
<td>145 Gy (125I LDR brachytherapy)</td>
<td>120 months</td>
<td>59.4 GyE ($^{125}$I LDR, 33 fractions, total delivered as sequential boost to tumor, 45 and 50.4 GyE dose levels for peri-prostatic tissue, and inguinal/internal iliac/perirectal LN, respectively). PBS with 2 lateral beams prescribed to the 90% IDL.</td>
<td>Concurrent chemotherapy</td>
</tr>
</tbody>
</table>

RT, radiation therapy; PBT, proton-beam therapy; AC, anal cancer; Gy, Gray; LDR, low dose rate; GyE, Gray-equivalent; LN, lymph nodes; PBS, pencil-beam scanning; MeV, megaelectron-volts; IDL, isodose line.

One published experience of PBT re-irradiation for AC is displayed in Table 5 (46). In this case report, the patient previously received low dose rate brachytherapy ($^{125}$I, minimum peripheral dose 145 Gy) to the prostate for low-risk prostate cancer. Nine years after brachytherapy, he was found to have pT2N0 SCC of the anal canal, resected via transanal excision with close margins. He was initially felt not to be a candidate for RT given his prior RT, and was surveilled. The following year, he was found to have recurrent, bulky, cT3N0 AC, spanning from 3–8 cm from the anal verge. He was offered abdominoperineal resection, but refused, and was then offered PBT re-irradiation, concurrently with chemotherapy. PBT was delivered via sequential boost to a dose of 45 GyE in 25 fractions to the peri-prostatic tissue, 50.4 GyE in 28 fractions to the...
inguinal, internal iliac, and perirectal lymph nodes, and 59.4 GyE in 33 fractions to gross tumor. The CTV to PTV expansion was 0.5 cm for the 45 and 50.4 GyE dose levels, and 0.3 cm for the 59.4 GyE dose level. PBT technique was PBS utilizing opposed lateral beams, matched to 2 16 MeV electron beams prescribed to the 90% isodose line. This arrangement was used, rather than standard PBT posterior obliques, to limit dose and toxicity to the region of prior RT in the prostate and prostatic urethra. Dosimetrically, all genitalia and femoral head constraints were achieved. The cumulative small bowel, prostate, and prostatic urethra maximum doses were 58 GyE (54 GyE desired), 52.7 GyE (45 GyE), and 25.5 GyE (25 GyE), respectively. Follow-up, disease-control, and toxicity outcomes were not reported.

Discussion

Herein, we provide the first systematic review of PBT re-irradiation in GI malignancies. Based upon the studies described, PBT re-irradiation for patients with recurrent or second primary GI cancers appears to be a promising option in terms of efficacy and safety, though with the need for additional data, with longer follow-up and larger samples to further validate these early experiences.

The ability of PBT re-irradiation to provide symptomatic palliation was demonstrated across many of the GI sites reported. In EC, Fernandes et al. (40) found that of the 10 patients who presented with dysphagia from recurrent tumor, 4 had complete and 3 had partial resolution of symptoms, while 1 had stable symptoms. In PC, Boimel et al. (45) found that all 6 patients who presented with painful recurrent disease reported resolution of pain following PBT re-irradiation. In RC, Berman et al. (43) reported that all 6 patients who presented with painful recurrent disease also reported resolution of their pain following PBT re-irradiation. While in some scenarios, it is possible that re-irradiation will be part of a curative-intent approach, it is also the unfortunate reality that even with PBT, cure may not be possible, and that the treatment intent may be durable LC and symptom palliation. It is encouraging that across multiple disease sites, PBT re-irradiation was effective in providing palliation.

In terms of disease-control, survival, and toxicity outcomes, while understanding that it is difficult to compare experiences between different modalities and studies, PBT re-irradiation for GI malignancies appears promising. In recurrent EC, Fernandes et al. (40) reported that 36% and 57% of patients remained free of LRR and DM at a median follow-up of 10 months following re-irradiation, with a median OS of 14 months, in an adenocarcinoma-predominant (71%) cohort, at a median of 32 months from their initial RT courses. In second primary EC, Patel et al. (41) found that all 3 patients remained free of LRR and DM, and alive, at a median follow-up of 26 months after re-irradiation, in an entirely SCC cohort, at a median of 30 years from their initial RT courses. Within these 2 studies, there is clear heterogeneity, as nearly all patients in the Fernandes study were treated for EC initially, to higher prior RT doses than those in Patel’s study, and with primarily adenocarcinoma histologies. In Patel’s report, the 3 initial RT courses were for non-GI malignancies, had maximum doses of 36 Gy, had as many as 41 years between courses, and were all SCC. This heterogeneity speaks to the variety of scenarios in which PBT re-irradiation can play a role in achieving cure or palliation in recurrent and second primary EC. Treatment was relatively well-tolerated, being administered with concurrent chemotherapy in the majority of patients in both of the above studies, with reasonable grade 3 toxicities, and 2 grade 5 toxicities, both favored to be due to progressive disease, rather than PBT. In addition, in Patel’s report, treatment was tolerated well enough that each patient, 2 of whom were felt to be medically inoperable prior to re-irradiation, all had curative-intent surgeries. One prior re-irradiation experience for EC, with 3D-CRT, reported tumor response rates of 50% at 3 months from re-irradiation, with shorter median follow-up times than the studies included, with fatal tracheoesophageal fistulae in 30% of patients (10). Another re-irradiation experience for EC (all SCC), using IMRT (56%) or 3D-CRT (44%), found that at a median follow-up of 87 months, 90% of patients experienced treatment failure, with 9%, 15%, and 24% rates of tracheoesophageal fistulae, pericardial/pleural effusion, and RT pneumonitis, respectively (47). Thus, PBT re-irradiation for EC compares favorably with published non-PBT experiences, potentially taking advantage of the physical properties of protons to spare dose to OARs and reduce toxicity, and is a viable option for patients with EC.

In PC, PBT re-irradiation provided reasonable LC (73%) and survival (median OS 17 months) at a median follow-up of 15.7 months, delivered concurrently with chemotherapy in most patients, with acceptable toxicity (13% acute grade 3, 7% acute grade 4, 7% acute grade 5 favored to be due to disease progression rather than PBT, and no late grade ≥2 toxicities) (42). These results compare favorably with published experiences of SBRT re-irradiation for PC, in which 1-year LC and median OS ranged from 62–78% and
9–14 months, respectively, with acute grade ≥3 and late grade ≥3 toxicity rates ranging from 0–10% and 6–7% (for SBO), respectively (13,14). While it is difficult to comment directly on the dosimetric differences between the PBT plans and the SBRT plans, it is possible that PBT’s rapid dose fall-off may have spared otherwise unavoidable bowel dose, while achieving comparable disease-control.

The data for PBT re-irradiation in recurrent or second primary liver tumors, while heterogeneous, demonstrate reasonable disease control (1-year LR 46%) and survival (median OS 14-61 months, with 5-year OS 49%), with excellent tolerability of treatment (2 acute grade ≥3 toxicities across both studies, no late grade ≥3 toxicities, and no cases of RILD) (43,44). The tolerability of effective therapy is particularly important in this patient population, as many have impaired baseline liver function, significant medical comorbidities, and exhausted alternative treatment options. In the studies referenced, patients were re-irradiated with PBT at least once, often for multiple liver tumors, with a variety of primary cancers (HCC, IHCC, and metastases), many prior non-RT treatments, and nearly one-third of patients with Child-Pugh B-C liver function in Oshiro et al. Thus, while the studies’ heterogeneity makes direct comparisons to other cohorts difficult, it also speaks to the breadth of scenarios in which PBT re-irradiation can be an effective option for patients with liver tumors. Further, prior studies of photon re-irradiation for HCC reported 36% and 25% rates of RILD and treatment-related death, respectively, underscoring the promise of PBT in this setting (48).

In RC, PBT re-irradiation also provided reasonable disease control and survival, with acceptable toxicity (4 acute grade 3, no acute grade ≥4 and 3 late grade 4 toxicities), at a median follow-up of 19.4 months (45). Two of the late grade 4 toxicities (SBO and entero-vaginal fistula) occurred in the same patient. The SBO occurred in the post-operative period, following PBT, and the fistula was felt to be due to tumor progression. This small study compares well with multiple prior reports of photon re-irradiation for RC. Sun et al. (11) found that hyperfractionated 3D-CRT re-irradiation with concurrent capecitabine for LR RC had an overall response rate of 60%, median OS of 32 months, 10% and 8% acute grade 3–4 diarrhea and granulocytopenia, respectively, and 1.4% rate of severe late toxicity (SBO), at a median follow-up of 24 months. Youssef et al. (12) found that IMRT re-irradiation with concurrent chemotherapy (81%) for LR RC had a 2-year LR rate of 53%, median OS of 22 months, 3% acute grade ≥3 toxicity (diarrhea), and 3% late grade ≥3 (sacral insufficiency fracture), at a median follow-up of 11.3 months. In addition, the results for PBT re-irradiation are comparable to that of carbon ion re-irradiation for LR RC, where Habermehl et al. (16) found that at a median follow-up of 7.8 months, the 1-year LC rate was 79% without grade ≥3 toxicities. Given the difference between the median follow-up intervals of the PBT and CIT studies, it is difficult to make a meaningful comparison at present.

In AC, our discussion is limited beyond treatment-planning aspects, as the sole published report of PBT re-irradiation for AC at this time did not report disease-control, survival, or toxicity outcomes (46). Additional studies in this scenario would be of value.

While PBT re-irradiation for GI malignancies was well-tolerated overall, there were instances of substantial toxicity felt to be RT-related, which physicians should consider carefully. In Boimel et al.’s (42) report of PBT re-irradiation for PC, 1 patient developed an acute grade 4 bleeding duodenal ulcer. This patient previously underwent biliary stent placement 9 months before PBT re-irradiation, then received PBT to the primary tumor, which contained duodenum within the PBT field. One week after completion of PBT, the ulcer was discovered and treated. One patient in this study suffered gastric outlet obstruction due to disease progression at the end of PBT re-irradiation, and subsequently required stent placement 3 days after PBT completion, complicated by fatal small bowel perforation, favored to be due to progressive disease and instrumentation, but potentially related to RT. These cases highlight the importance of exercising caution when delivering RT near the duodenum, an organ that commonly exhibits RT toxicity. Additionally, a prior dosimetric comparison of PBT and IMRT for unresectable PC found that while PBT decreased duodenal dose in low-dose regions, it increased duodenal dose in the mid-high-dose regions (49). Thus, even with the most conformal techniques, including PBT, significant and fatal duodenal toxicity can still occur, particularly in the setting of progressive disease or instrumentation, and these should be considerations when deciding whether or not to offer re-irradiation near the duodenum.

Two studies included generated comparison VMAT/IMRT plans to analyze dosimetric differences from the treated PBT plans. In Patel et al.’s (41) report, PBT reduced mean heart and lung doses, spinal cord maximum dose, and lung V5Gy for all patients, as compared to VMAT, while lung V20Gy and V30Gy were higher for PBT in the
2 patients treated with PS. Berman et al. (45) found that PBT significantly decreased bowel V10Gy and V20Gy, and the dose to 200 and 150 cc of bowel, as compared to IMRT. These are consistent with Thompson et al.’s (49) findings that PBT significantly reduced stomach, duodenal and small bowel dose in low-dose regions, as compared to IMRT. While the toxicity results in the studies included are encouraging, it still remains to be seen in a prospective, controlled, comparative setting whether these dosimetric advantages for PBT will translate into clinical advantages over alternative RT modalities.

There are a number of limitations to this publication. It is possible that additional PBT re-irradiation literature for GI malignancies exists, either in non-English languages, or outside of the PubMed search engine. Another limitation is that nearly all PBT treatments delivered across each of the studies were delivered with techniques other than PBS. It is possible, as evidenced by Patel et al.’s (41) case series, that PBS may provide reduction of OAR doses beyond that of PS, which could translate into further clinical benefit. If so, the results in this analysis may overestimate PBT toxicity or underestimate a potential benefit. A specific limitation within McDuff et al.’s (44) report is that 90% of patients did not receive PBT, and the majority of outcomes reported did not stratify into PBT versus non-PBT modalities. While it was specified that neither of the RILD cases occurred in PBT patients, beyond the overwhelmingly positive toxicity outcomes for the entire cohort, it is difficult to draw more meaningful conclusions without further specification. Many of the reports included in this analysis were single-arm, retrospective studies of PBT, without discrete, randomized, controlled, or propensity-matched comparisons to non-PBT modalities. Thus, any comparisons between the PBT studies included and other re-irradiation studies must be interpreted with caution. Further prospective, randomized comparisons between PBT and standard modalities, as well as other advanced modalities, such as CIT, can help provide additional clarity. Some of the studies included had short median follow-up intervals, and may not have captured additional outcomes that occurred with longer follow-up. To better assess PBT’s role in the re-irradiation setting for GI malignancies, longer-term follow-up is warranted.

Studies were assessed for bias, as in Verma et al.’s (38) review of PBT re-irradiation, by considering sample size, study design, consistency of presented results, patient eligibility/selection, outcome measures, follow-up intervals, potential for selective reporting/publication bias, external validity, funding bias, and discussion of limitations. Many studies included in our analysis were limited by small sample size, retrospective single-arm design, differing definitions of outcomes, differing statements of patient eligibility/selection, short follow-up, potential for selective reporting/publication bias, and limited external validity. Funding bias was not observed. Study limitations were discussed, to varying degrees. In general, there is risk of bias within the studies, and the evidence quality is limited by the above issues.

Based upon the published experiences to date, PBT re-irradiation for recurrent or second primary GI malignancies appears to be an effective option for palliation, with encouraging disease-control, survival, and toxicity outcomes, favorable dosimetric comparisons to standard RT modalities, and compares well with published non-PBT GI re-irradiation experiences. In our own experience, we have learned that re-irradiation with PBT is extremely resource intensive, from obtaining old records and creating plan sums, to debate in tumor boards to help select patients. The importance of careful patient selection cannot be overstated. In general, we attempt to limit PBT re-irradiation to patients with good performance statuses, more than 1 year from prior RT, and reasonable target volumes, with careful attention to OAR doses in past and re-irradiation courses. Of particular note is the risk of stents and tubes within hollow viscous organs getting high cumulative RT doses. It is not known if these mechanical stressors increase toxicity risk, but several of the severe PBT re-irradiation toxicities occurred in the setting of iatrogenic microtraumas. Ultimately, the complicated decision to re-irradiate is colored by the balance between the known (often 100%) risk of tumor-associated complications compared to the unknown risk of re-irradiation toxicities, where there are no other therapeutic options. Given the novelty of PBT and short follow-up in the published studies, additional study is warranted to determine if the dosimetric advantages seen in PBT will translate into short- and long-term toxicity benefits.

Acknowledgments

None.

Footnote

Conflicts of Interest: JM Metz is on the advisory board of Varian Medical Systems, Ion Beam Applications, and Provision. JP Plastaras serves on committees for the American Board of Radiology, the American Society for
Radiation Oncology, and the International Lymphoma Radiation Oncology Group. The other authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

References


